Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate a NULOJIX® (belatacept) based regimens as a means of
improving long-term graft function without increasing the risks of immunologic graft injury
by avoiding both calcineurin inhibitors (CNIs) and corticosteroids.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)